Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine.

Denys D, Klompmakers AA, Westenberg HG.

Psychopharmacology (Berl). 2004 Nov;176(2):195-203. Epub 2004 May 11.

PMID:
15138756
2.

Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex.

Ago Y, Nakamura S, Baba A, Matsuda T.

Neuropsychopharmacology. 2005 Jan;30(1):43-51.

4.

ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.

Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY.

Psychopharmacology (Berl). 2005 Dec;183(2):144-53. Epub 2005 Nov 9.

PMID:
16220333
5.
6.

In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine.

Jordan S, Kramer GL, Zukas PK, Moeller M, Petty F.

Synapse. 1994 Dec;18(4):294-7.

PMID:
7886621
7.

Prazosin addition to fluvoxamine: A preclinical study and open clinical trial in OCD.

Feenstra MGP, Klompmakers A, Figee M, Fluitman S, Vulink N, Westenberg HGM, Denys D.

Eur Neuropsychopharmacol. 2016 Feb;26(2):310-319. doi: 10.1016/j.euroneuro.2015.12.008. Epub 2015 Dec 11.

PMID:
26712326
9.

Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex.

Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP.

Neuropsychopharmacology. 2000 Sep;23(3):250-62.

10.

Fluvoxamine, a selective serotonin reuptake inhibitor, suppresses tetrahydrobiopterin levels and dopamine as well as serotonin turnover in the mesoprefrontal system of mice.

Miura H, Qiao H, Kitagami T, Ohta T, Ozaki N.

Psychopharmacology (Berl). 2005 Jan;177(3):307-14. Epub 2004 Jul 29.

PMID:
15290002
11.

Fluvoxamine enhances prefrontal dopaminergic neurotransmission in adrenalectomized/castrated mice via both 5-HT reuptake inhibition and σ(1) receptor activation.

Ago Y, Yano K, Hiramatsu N, Takuma K, Matsuda T.

Psychopharmacology (Berl). 2011 Oct;217(3):377-86. doi: 10.1007/s00213-011-2293-5. Epub 2011 Apr 13.

PMID:
21487652
12.
13.

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.

Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW.

Neuropsychopharmacology. 2002 Nov;27(5):699-711.

14.
15.

Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats.

Kitaichi Y, Inoue T, Nakagawa S, Boku S, Kakuta A, Izumi T, Koyama T.

Eur J Pharmacol. 2010 Nov 25;647(1-3):90-6. doi: 10.1016/j.ejphar.2010.08.026. Epub 2010 Sep 9.

PMID:
20816814
16.
17.

Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.

Huang M, Li Z, Dai J, Shahid M, Wong EH, Meltzer HY.

Neuropsychopharmacology. 2008 Nov;33(12):2934-45. doi: 10.1038/npp.2008.20. Epub 2008 Apr 16.

18.
20.

Lack of enhanced effect of antipsychotics combined with fluvoxamine on acetylcholine release in rat prefrontal cortex.

Ago Y, Sato M, Nakamura S, Baba A, Matsuda T.

J Pharmacol Sci. 2006 Dec;102(4):419-22. Epub 2006 Nov 28.

Supplemental Content

Support Center